Vaccine Info

TG4050 Ovarian Cancer Therapeutic Vaccine

Description

TG4050 is an individualized MVA-based immunotherapy designed to stimulate and educate the immune system of patients to recognize and destroy tumor cells. 

Indication

TG4050 is indicated for ovarian cancer patients who have already received first-line treatment. 

TG4050 is designed to target a panel of patient-specific mutations selected using NEC's Neoantigen Prediction System

Dosage

TG4050 will be administered in the Phase 1 Clinical Trial as subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.

Clinical Trial NCT03839524: A Trial Evaluating TG4050 in Ovarian Carcinoma

  • This is a multicenter, open-label, single-arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Updated
September 4th, 2019